Navigation Links
Mechanism of Action of ABIVAX's First-in-class Anti-HIV Drug Published Today in Peer-reviewed Journal Retrovirology
Date:4/13/2015

PARIS, April 13, 2015 /PRNewswire/ --

Novel mechanism of action - prevention of viral RNA exit from nucleus of infected cells - associated to unique anti-viral properties 

Unlike any current anti-HIV drug: 

  • Drop of viral load induced by ABX464 is sustained following treatment cessation 
  • No HIV mutants emerge from ABX464 treatment 

On-going phase II clinical trial in patients 

ABIVAX, a clinical phase II stage biotechnology company developing first-in-class anti-viral drugs and vaccines, announced publication today of the mechanism of action of ABX464 in the April issue of Retrovirology: http://www.retrovirology.com/content/12/1/30/abstract . ABX464 is a novel small molecule in phase II clinical trial that inhibits HIV replication through an entirely new mechanism.

The pioneering research described in the scientific publication was conducted by six premier research institutions from France, Canada and Switzerland, in addition to the ABIVAX laboratories, under the leadership of Professor Jamal Tazi of the Molecular Genetics Institute at CNRS in Montpellier, France. The research team was able to demonstrate that:

    1. ABX464 blocks viral replication by preventing the export of viral RNA from the nucleus to the cytoplasm in infected cells. This transport is normally mediated by a viral protein called Rev, and the activity of Rev is efficiently inhibited by ABX464. Never targeted before, Rev has been postulated of potential interest for HIV treatment for some time, but ABX464 is the first molecule under development aimed at inhibiting it.


Jamal Tazi, senior author of the article, stresses that "ABX464 targets an event after the genetic material of the virus has been integrated in the cell. This way, ABX464 not only prevents the infection of new cells, but it is the only drug to datethat can act on already infected cells and prevent the synthesis of new viruses." He added, "Therefore the difficult-to-reach reservoir of infected cells remaining under current HIV therapy may become reachable."

ABX464 leads to a significant and sustained reduction of viral load, which lasts for several weeks after cessation of treatment in a preclinical reference model. In contrast, the control group, receiving current state of the art triple anti-HIV therapy, had an immediate rebound of the viral load after stopping the treatment. Current treatments in patients merely hold the virus at bay whereas ABX464 may lead to durable suppression of viral load.

    2. ABX464 does not affect the physiological cellular RNA-processing in humans. This is an important finding, as it suggests that ABX464 is specific for HIV RNAs and does not influence the synthesis of human proteins.


    3. ABX464 does not lead to HIV mutants that become resistant to treatment. Thus, in contrast to all other anti-HIV drugs, ABX464 may be effective as a monotherapy.


Professor Mark Wainberg, former President of the International AIDS Society and co-author of the publication, said, "We are very encouraged by the data obtained with ABX464, which has the potential to become part of afunctional cure strategy for patients with HIV and AIDS."

The supplementary information in the Retrovirology article reports successful toxicology and pharmacokinetic studies.

Didier Scherrer, Ph.D., Vice-President of Small Molecules R&D at ABIVAX said, "As aresult, ABIVAX has received authorization to carry out clinical studies with ABX464, followingthe phase Itrial in human volunteers which wasinitiated in early 2014. Based on the safety and PK data, ABX464 progressed to a phase IIa trial in patients, which was begun several weeks ago. The goal of this study is to determine the optimaldose and frequency of administration."

Professor Hartmut J. Ehrlich, M.D., CEO of ABIVAX, concluded, "We are very excited about the data obtained so far with ABX464, as they indicate that ABX464 is safe and may be less frequently administered than standard therapies, thereby potentially improving outcomes and compliance, helpingto reduce healthcare costs and offering broader access to treatment."

ABX464 is the first candidate molecule coming from ABIVAX's proprietary anti-viral drug technology platform that focuses on viral RNAs. It has been generated from an in-depth understanding of the processing of viral RNA within the human host cell.

About ABIVAX 

ABIVAX is an advanced clinical stage biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral compounds and human vaccines to treat some of the world's most important infectious diseases, including HIV/AIDS and chronic Hepatitis B.

ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months.

ABX464 has been developed using ABIVAX' anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients' clear important pathogenic viruses.

Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy.

ABIVAX was founded by Dr. Philippe Pouletty, M.D. , managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation.

For more information, please visit the company's website: http://www.ABIVAX.com

Contacts 

ABIVAX 

Prof. Hartmut J. Ehrlich, CEO

Press Relations 

Citigate Dewe Rogerson  

Ari Levine - Lucie Larguier (Paris)

David Dible (London)

ari.levine@citigate.fr / david.dible@citigatedr.co.uk

+33-1-53-32-84-71 / +44-20-7282-2949

ALIZE RP 

Caroline Carmagnol and Valentine Boivin

abivax@alizerp.com

+33-1-44-54-36-63 / +33-6-64-18-99-59


'/>"/>
SOURCE ABIVAX
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
2. Understanding the molecular mechanisms underlying Alzheimers disease
3. UCSB researchers identify the mechanisms underlying salt-mediated behaviors in fruit flies
4. New mechanism for human gene expression discovered
5. Brain dysfunctions: Shared mechanisms in fragile X syndrome, autism and schizophrenia
6. Newly discovered mechanism propels micromotors
7. York researchers discover important mechanism behind nanoparticle reactivity
8. Key Mechanism Identified In Pediatric Bone Cancers That Allows Proliferation Of Tumor-Forming Stem Cells
9. Probiotic Action Announces Probiotics Lead the Digestive Health Market
10. Probiotic Action Explains New Research that Probiotics Help Reduce Stress Side Effects
11. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
(Date:2/15/2017)... ... 2017 , ... Diameter Health (Diameter) and Lantana ... in the hands of Lantana analysts. The high-performance platform of Diameter combined with ... entities – all those mining value from clinical data – to get the ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):